5719
Pharmacoeconomic evaluation of pomalidomide (imnovid) use in treatment of patients with relapsed or refractory multiple myeloma who have received at least two lines of therapy comprising lenalidomide and bortezomib
This paper represents the results of pharmacoeconomic study of the drug pomalidomide use in treatment of patients with relapsed or refractory multiple myeloma (MM) with more than 50% reduction in M protein, who have received at least two lines of therapy comprising lenalidomide and bortezomib. Lenalidomide and bortezomib were used as comparative treatment options in the study. The pharmacoeconomic study was carried out using the methods for analysis of efficiency, cost, cost-effectiveness, sensitivity and impact on the budget under frame of the medicinal assistance program for people suffering from hemophilia, cystic fibrosis, pituitary dwarfism, Gaucher’s disease, formation of malignant lymphoid haematogenic and related tissues, multiple sclerosis, as well as organ and/or tissue transplants (hereinafter referred to as the Seven Nosologies (VZN) Program). The time horizon of the «impact on the budget» analysis for the “Seven Nosologies” program was consisted of 4 years (2015–2018). The pharmacoeconomic analysis showed that pomalidomide can be recommended for inclusion in the “Seven Nosologies” federal program within the existing budget. From the perspective of the cost-effectiveness analysis, pomalidomide is the dominant option, since the use of pomalidomide in the MM treatment has a significant advantage over lenalidomide and bortezomib therapy in terms of «cost of the average time to disease progression» and «value of survival time». In other words, pomalidomide therapy has the lowest cost of achieved efficiency unit. Analysis of the impact on the budget in case of pomalidomide (Imnovid) inclusion into the pattern of government procurement as part of the “Seven Nosologies” program for the target period (2016–2018) showed that pomalidomide inclusion will not lead to increase the program budget.
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF
Bibliography link:
Kulikov A.Y., TishchenkoD.G. Pharmacoeconomic evaluation of pomalidomide (imnovid) use in treatment of patients with relapsed or refractory multiple myeloma who have received at least two lines of therapy comprising lenalidomide and bortezomib // Pharmacoeconomics: theory and practice. - 2016. - Vol.4, №1. - P.157-164 DOI: https://doi.org/10.30809/phe.1.2016.33
Comments0